Lorem Therapeutics, a US-based cancer-focused drug developer, was spun out of Johns Hopkins University yesterday with funding from commercialisation firm IP Group.
Financial terms of the deal have not been disclosed. Lorem will also receive support from FastForward, which is operated by the institution’s tech transfer office, Johns Hopkins Technology Ventures, and offers access to office space, services and funding opportunities.
Lorem Therapeutics will develop early-stage therapeutics for several cancer indications, with a specific focus on bridging the gap from…
